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Abstract
Background: In vivo efficacy assessments of the first-line treatments for Plasmodium falciparum malaria are
essential for ensuring effective case management. In Ethiopia, artemether-lumefantrine (AL) has been the first-line
treatment for uncomplicated P. falciparum malaria since 2004.
Methods: Between October and November 2009, we conducted a 42-day, single arm, open label study of AL for P.
falciparum in individuals >6 months of age at two sites in Oromia State, Ethiopia. Eligible patients who had
documented P. falciparum mono-infection were enrolled and followed according to the standard 2009 World
Health Organization in vivo drug efficacy monitoring protocol. The primary and secondary endpoints were PCR
uncorrected and corrected cure rates, as measured by adequate clinical and parasitological response on days 28
and 42, respectively.
Results: Of 4426 patients tested, 120 with confirmed falciparum malaria were enrolled and treated with AL. Follow-
up was completed for 112 patients at day 28 and 104 patients at day 42. There was one late parasitological failure,
which was classified as undetermined after genotyping. Uncorrected cure rates at both day 28 and 42 for the per
protocol analysis were 99.1% (95% CI 95.1-100.0); corrected cure rates at both day 28 and 42 were 100.0%.
Uncorrected cure rates at day 28 and 42 for the intention to treat analysis were 93.3% (95% CI 87.2-97.1) and 86.6%
(95% CI 79.1-92.1), respectively, while the corrected cure rates at day 28 and 42 were 94.1% (95% CI 88.2-97.6) and
87.3% (95% CI 79.9-92.7), respectively. Using survival analysis, the unadjusted cure rate was 99.1% and 100.0%
adjusted by genotyping for day 28 and 42, respectively. Eight P. falciparum patients (6.7%) presented with
Plasmodium vivax infection during follow-up and were excluded from the per protocol analysis. Only one patient
had persistent parasitaemia at day 3. No serious adverse events were reported, with cough and nausea/vomiting
being the most common adverse events.
Conclusions: AL remains a highly effective and well-tolerated treatment for uncomplicated falciparum malaria in
the study setting after several years of universal access to AL. A high rate of parasitaemia with P. vivax possibly
from relapse or new infection was observed.
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Artemisinin-based combination therapy (ACT) has now
been adopted by all countries in sub-Saharan Africa for
the first-line treatment of uncomplicated Plasmodium
falciparum malaria [1]. Routine monitoring of first-line
therapies is crucial to ensure use of efficacious regimens
and to maintain the progress made to date in decreasing
malaria morbidity and mortality [2,3].
In Ethiopia, malaria is a leading cause of morbidity
and mortality [1]. In 2007-2008, malaria was the most
common cause of outpatient visits and admissions,
accounting for 12% of all visits and 10% of admissions
[4]. Unlike much of Africa, both P. falciparum and Plas-
modium vivax contribute to malaria morbidity in Ethio-
pia, in relative proportions of 60% and 40%, respectively.
However, this relative proportion varies both temporally
and geographically, with published ranges of 22-89% for
P. falciparum and 11-67% for P. vivax [5,6]. Further-
more, malaria affects all age groups.
Chloroquine (CQ)-resistant P. falciparum became a
major public health threat in the early 1990s in Ethiopia
[7]. By the late 1990s, 86-88% treatment failure rates
with CQ were being reported, which prompted change
of first-line treatment to sulphadoxine-pyrimethamine
(SP) in 1998 [8,9]. In 2003, a nation-wide study evaluat-
ing SP efficacy showed 36% and 72% treatment failure
rates with 14-day and 28-day follow-up, respectively
[10]. Following a large-scale malaria epidemic that
ravaged Ethiopia in 2003 [11] and the concomitant
recognition of wide-spread resistance to SP [10,12], the
Federal Ministry of Health (FMOH) adopted arte-
mether-lumefantrine (AL) for first-line treatment of
uncomplicated P. falciparum malaria in Ethiopia [1].
Prior to this change, baseline efficacy of AL was evalu-
ated and a 1% treatment failure rate was noted [13].
More recent evaluations of AL efficacy in Ethiopia
noted PCR uncorrected cure rates of 93% [14] and 96%
[15]. AL is a blood schizonticide and has been shown to
be effective, well-tolerated and fast-acting [16-18]. It was
also the first co-formulated ACT meeting international
good manufacturing practice standards and was pre-
qualified by the World Health Organization (WHO).
In recent decades, spread of resistance to newly intro-
duced anti-malarial therapies has been seen with dire
consequences for malaria control. Reports of artemisinin
resistance from the Thai-Cambodian border, the epicen-
ter of drug resistance, raise global concern for the long-
term efficacy of ACT [19,20]. Six years have passed
since AL was adopted as first-line therapy in Ethiopia,
which coincided with the FMOH’s ambitious plan to
provide universal access to prompt malaria diagnosis
and treatment–as recently recommended by WHO [18]
- through a network of 15,000 community-level health
posts [21]. Continuously monitoring AL drug efficacy is
critical to allow for sufficient time to explore alternatives
and change national policy as soon as AL efficacy begins
to decline.
The objectives of the study reported here were (i) to
assess the in vivo efficacy of AL for P. falciparum at fol-
low-up durations of 28 and 42 days, and (ii) to assess
secondary outcomes of haematologic response, gameto-
cytaemia, and rates of fever and parasite clearance.
Methods
Study site and enrollment
The study was conducted at two established FMOH
health facilities, Bishoftu Malaria Clinic (elevation 1,850
metres) and Bulbula Health Center (elevation 2,150
metres), in Oromia Regional State, Ethiopia, from Octo-
ber to November, 2009. Plasmodium falciparum and P.
vivax are endemic at both sites, and the study was con-
ducted during the peak malaria transmission season.
Malaria in Ethiopia is highly unstable, with potential for
focal or large-scale epidemics. In Ethiopia, malaria trans-
mission is largely determined by climate and altitude,
with the peak transmission season occurring between
September and December, after the main rainy season
from June to August. Recent household surveys of all
ages have noted parasite prevalence rates of 0.3 and
0.9% [21,22] while a school-based survey of children 5-
18 years noted a prevalence of 0.6% [23] in Oromia, all
consistent with hypoendemic transmission.
Patients
Patients with P. falciparum mono-infection, with parasi-
taemia level of 1,000-100,000 asexual forms per μlw e r e
enrolled. Additional inclusion criteria included age >6
months, weight >5 kg, and axillary temperature ≥37.5°C
or history of fever in the past 24 hours. Only patients
l i v i n gw i t h i n2 0k mo ft h ee n r o l l i n gs t u d ys i t ew e r e
included to facilitate follow-up. Exclusion criteria
included detection of any Plasmodium infection besides
falciparum mono-infection, any signs or symptoms of
severe illness, severe malnutrition, severe anaemia (hae-
moglobin (Hg) < 5 g/dL), known hypersensitivity to AL,
presence of another infection or major co-morbid condi-
tions, pregnancy, or breastfeeding.
The study received ethical clearance from the U.S. Cen-
ters for Disease Control and Prevention, Columbia Uni-
versity, and the Ethiopian Public Health Association.
W r i t t e ni n f o r m e dc o n s e n tw a so b t a i n e df r o ma d u l t
patients and guardians of enrolled children. Written
assent was also obtained from children 7-17 years of age.
Clinical and laboratory procedures
To assess AL therapeutic efficacy for uncomplicated P.
falciparum mono-infection based on clinical and parasi-
tological parameters, a prospective, 42-day, open-label in
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WHO in vivo protocol for measuring anti-malarial drug
efficacy for areas of low to moderate malaria transmis-
sion was conducted [3,24]. Blood films were taken at
initial presentation for all patients at the Bishoftu
Malaria Clinic (as routinely done). Once a positive P.
falciparum infection was identified by microscopy, the
patient was screened for study eligibility criteria. At Bul-
bula Health Center, all patients attending the outpatient
ward were initially evaluated by the clinical staff and
those with fever or a history of fever were referred for
malaria testing (as routinely done). Once the patient was
noted to have microscopy-confirmed P. falciparum
infection, the study staff screened the patient for inclu-
sion in the study.
After meeting the inclusion criteria and consenting to
enrollment into the study, all patients underwent hae-
moglobin testing (Hemocue Hb 201+, Angelholm, Swe-
den) and filter paper blood spot collection. All women
age 13-49 years underwent a urine pregnancy test and
those testing positive were excluded from the study.
Thick and thin blood films were prepared according to
standard procedures, i.e. by staining for ten minutes
with 10% Giemsa [24] and read by two independent,
blinded microscopists. Parasite density was estimated
based on the number of asexual parasites observed
against 200 leukocytes assuming 8,000 leukocytes per μl.
Patients with discrepant species results were excluded
from the study. Slides with parasite densities differing by
more than 20% between microscopists were reassessed
by a third microscopist, with the third reading consid-
ered final. Smears were determined to be negative only
after examining 100 high power fields.
Patients were interviewed and examined by the study
clinician. The patients were given oral AL (Coartem
®,
Novartis Pharma, Basel, Switzerland) based on weight
according to national policy [25]. AL was packaged in
fixed-dose combination tablets, each containing 20 mg
of artemether and 120 mg of lumefantrine. AL was
administered according to the package insert twice daily
for three days; those patients weighing 5-14 kg were
given one tablet, 15-24 kg two tablets, 25-34 kg three
tablets, and ≥35 kg four tablets at each of six dosing
intervals. The initial and each morning dose were
directly observed by the study staff and given with milk
biscuits to increase absorption [26,27]. Patients were
monitored for 60 minutes; a full or half a dose was re-
administered if the patient vomited the drug within 30
or 31-60 minutes, respectively. If the patient vomited
again, he or she was referred to the hospital and with-
drawn from the study. Patients were instructed to take
the evening dose with food. On follow-up days 1-3,
patients were asked if the drug was taken properly the
previous night. In order to facilitate twice daily dosing
of AL, all patients presenting after 3:00 PM were
excluded from the study. Antipyretics were given for
temperatures > 39°C as per national policy [25]. Ferrous
sulfate, folate, and mebendazole (if aged >1 year) were
given to all children with haemoglobin <10 mg/dl as per
Integrated Management of Childhood Illness (IMCI)
guidelines [28]. Quinine (10 mg/kg every 8 hours for 7
days), the second-line treatment as per national policy,
was administered as rescue therapy [25].
Follow-up
Patients were followed-up for 42 days and asked to
return on days 1-3, 7, 14, 21, 28, 35, and 42 post-AL
therapy initiation, as well as any other interim day, if ill.
The study site facilities were open from 8:00 AM to
6:00 PM, and after hours care was also available. Stan-
dardized follow-up included documentation of history-
taking to elicit symptoms, adverse events, and any con-
comitant therapy, and physical examination including
axillary temperature measurement. Finger pricks for fol-
low-up blood films were taken on scheduled days 2, 3,
7, 14, 21, 28, 35, 42, and at any unscheduled visit. Hae-
moglobin was measured weekly and filter papers were
collected on day 7 for drug level testing and on any day
of failure for molecular testing. All filter papers were
dried and stored in plastic storage bags with desiccant
and humidity indicators. At the conclusion of the study,
all day 0 slides were submitted to the national labora-
tory for quality control purposes. The filter papers for
drug level testing were sent to the U.S. Centers for Dis-
ease Control and Prevention in Atlanta, USA, while the
filter papers collected for molecular testing were sent to
the Ethiopian Health and Nutrition Research Institute
(EHNRI) in Addis Ababa, Ethiopia.
Outcomes
Efficacy was assessed by clinical and parasitological out-
comes using WHO definitions, with a 42-day follow-up
period [3]. As per WHO definitions, early treatment fail-
ure (ETF) was defined as development of severe signs or
symptoms, or insufficient parasitological response by
day 3. Patients with P. falciparum parasitaemia occur-
ring between 4 and 42 days without fever were classified
as late parasitological failure (LPF) and those with fever
as late clinical failure (LCF). If no failure was recorded,
it was classified as adequate clinical and parasitological
response (ACPR).
Laboratory analysis
To distinguish between recrudescence and reinfection,
three to four drops of blood were collected on filter
paper at day 0 prior to treatment and on any day of
recurrent parasitaemia. DNA was extracted from blood-
spots dried on filter papers by soaking overnight in 1 ml
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ment was then washed twice in 1 ml of PBS and boiled
for 8 min in 100 μlP C R - g r a d ew a t e rw i t h5 0μl 20%
chelex suspension (pH 9.5). Recrudescent and new
infections were differentiated by typing the highly poly-
morphic repeat region of MSP2 as previously described
[29]. Pre- and post-treatment samples for each patient
were compared by running the amplified MSP2 pro-
ducts in adjacent lanes of 2% agarose gels. Recrudescent
infections were characterized as having at least one
identical allele (within 15 bp) present in both pre- and
post-treatment samples. Samples where no alleles
matched pre- and post-treatment were classified as new
infections. If either pre- or post-samples failed to
amplify, they were classified as undetermined. All mole-
cular testing was conducted at EHNRI in Addis Ababa,
Ethiopia.
Lumefantrine levels from day 7 dried blood spots were
assessed in case of treatment failure. Lumefantrine levels
in capillary whole blood were determined by high-per-
formance liquid chromatography using a modified
method described by Blessborn et al [30]. Briefly, lume-
fantrine was extracted from 8-mm diameter sections of
dried blood-saturated filter paper using acetic acid and
acetonitrile containing internal standard followed by
solid-phase extraction. The filter papers were not treated
with tartaric acid prior to blood application as suggested
by Blessborn et al [30], resulting in lower recovery effi-
ciency and a higher limit of quantification of 212 ng/ml.
Chromatographic separation was accomplished using a
Z o r b a xS B - C N ,3 . 0×2 5 0m m ,5m i c r o nc o l u m n( A g i -
lent Technologies, Santa Clara, CA, USA) with UV
detection at 335 nm. Assay accuracy was determined to
be 3.8% at 212 ng/ml and 11.4% at 5291 ng/ml.
Statistical analysis
Primary efficacy outcomes included day 28 ACPR, both
PCR corrected and uncorrected. Secondary outcomes
included day 42 ACPR (PCR corrected and uncor-
rected), haematologic outcomes, and rates of fever and
parasite clearance. With treatment failure of AL for P.
falciparum being reported at ≤5%, 10% was chosen as
the estimated therapeutic failure rate. Assuming an esti-
mated ACPR of 90% and a 20% loss to follow-up at 42
days, a sample size of 120 subjects was determined to
result in a 95% exact binomial confidence interval from
82.4%-95.1%.
All case record forms were pre-printed and organized
into individual patient record folders. At the end of each
c l i n i cv i s i t ,t h ef o r m sw e r ec h e c k e db yt h en u r s ef o r
completeness prior to discharging the patient. All
patient records were reviewed for accuracy by the site
supervisor. All data were entered into both Microsoft
ACCESS (Microsoft, Redmond, WA, USA) database and
the Microsoft Excel (Microsoft, Redmond, WA, USA)
standard database developed by WHO [3], and analyzed
using SAS 9.2 (SAS Institute, Cary, NC, USA). Data
were double-entered and any discrepancies resolved by
referring to the original paper form. Patients enrolled in
the study erroneously and later found not to meet the
inclusion criteria were excluded from all analyses. The
intention-to-treat (ITT) analysis included all enrolled
patients who met the inclusion criteria and took at least
one full dose of AL. Patients lost to follow-up or with-
drawn from the study were considered as failures. Per
protocol (PP) analysis of outcomes included data for
patients who had completed follow-up. Those patients
lost to follow-up or withdrawn due to protocol viola-
tions were excluded from the PP analysis. In addition,
the cumulative risk of failure using the Kaplan-Meier
method was computed for 28- and 42-days of follow-up.
For the Kaplan-Meier analysis, lost to follow-up, with-
drawals, and parasitaemia with a different species were
censored on the last day of follow-up. Comparisons
between groups were made using c
2 test or Fisher’s
exact test for categorical variables and the Student’st -
test or Wilcoxon rank sum test (i.e. for non-parametric
outcomes) for continuous variables. A two-sided p-value
< 0.05 was considered statistically significant.
Results
Patients
Of the 4,426 patients tested from the two study sites, 961
were positive for malaria parasites, and 260 tested posi-
tive for P. falciparum mono-infection. At the Bishoftu
Malaria Clinic, the slide positivity rate was 16.5% (455/
2,764) of which P. falciparum mono-infection accounted
for only 11.4% (52/455); whereas, at Bulbula Health Cen-
ter, the slide positivity rate was 30.7% (510/1,662) of
which P. falciparum mono-infection accounted for 40.8%
(208/510). In summary, 120 patients were enrolled. Trial
profile and reasons for exclusion are shown in Figure 1.
The majority of the excluded patients presented late in
the afternoon and were not enrolled to ensure appropri-
ate timing of the second dose of AL. One patient was
incorrectly enrolled, with gametocytes only and no asex-
ual parasites on day 0. This patient was withdrawn from
the study and excluded from all analyses.
Baseline characteristics of the patients (N = 119) are
shown in Table 1 stratified by children ≤5 years of age (n
= 23) and those >5 years of age (n = 96). A significantly
greater proportion of female patients were enrolled as chil-
dren ≤5 years of age (47.8%) than in the group >5 years of
age (20.8%) (p-value < 0.01). The geometric mean parasite
density (GMPD) was significantly higher for children ≤5
years of age (27,198 parasites/μl; 95% confidence interval
(CI) 19,468-37,996) than for those >5 years of age (14,500
parasites/μl; 95% CI 11,500-18,282) (p-value = 0.01).
Hwang et al. Malaria Journal 2011, 10:209
http://www.malariajournal.com/content/10/1/209
Page 4 of 10Furthermore, the presence of P. falciparum gametocytes at
enrollment was significantly higher for those aged ≤5y e a r s
(26.1%) than those aged >5 years (8.3%) (p-value = 0.03).
Although only 23.5% of patients reported owning a bed
net of any type, 70.6% reported living in a household that
had been sprayed with insecticide in the past 12 months.
Bed net ownership and indoor residual spraying of house-
holds with insecticide did not differ significantly between
the two age groups.
Treatment outcomes
Follow-up was completed for 112 patients to day 28 and
104 to day 42 (Figure 1). There were no early treatment
failures and only one late parasitological failure, which
occurred on day 28 (Table 2). Molecular genotyping to
distinguish recrudescence from reinfection for the one
late parasitological treatmen tf a i l u r es a m p l ew a sc l a s s i -
fied as undetermined due to no amplification of the
sample in both the pre- and post-treatment samples.
This one late parasitological failure occurred in a 24-
year-old male on day 28 of follow-up with parasite den-
sity of 3,840 parasites/μL and no symptoms.
Four patients were lost to follow-up and three with-
drew from the study (after missing an evening dose of
AL). The uncorrected cure rates at day 28 and 42 for
the PP analysis were 99.1% (95% CI 95.1-100.0) and
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Figure 1 Trial Profile. Screening, Enrollment, and Follow-up of Patients
Table 1 Baseline characteristics of enrolled patients, stratified by age group under 5 years and over 5 years
Characteristic ≤5 years of age enrolled >5 years of age enrolled Total enrolled
n = 23 95% CI n = 96 95% CI N = 119 95% CI
Female (%) 47.8 26.8-69.4 20.8 13.2-30.3 26.1 18.4-34.9
Mean age (years) 3.1 2.6-3.6 19.9 17.4-22.5 16.7 14.3-19.1
Mean height (cm) 92.7 88.2-97.1 154.2 149.8-158.7 142.4 136.6-148.1
Mean weight (kg) 13.3 12.5-14.2 43.4 40.3-46.5 37.6 34.3-40.9
Mean temperature (°C) 37.6 37.1-38.1 37.5 37.3-37.7 37.5 37.3-37.7
Mean haemoglobin (g/dL) 10.4 9.6-11.1 13.2 12.7-13.6 12.6 12.2-13.1
Geometric Mean Parasite Density (parasites/μl) 27,198 19,468-37,996 14,500 11,500-18,282 16,374 13,375-20,045
Gametocytes present (%) 26.1 10.2-48.4 8.3 3.7-15.8 11.8 6.6-19.0
Owns a bed net (%) 21.7 7.5-43.7 24.0 15.8-33.8 23.5 16.2-32.2
IRS in past 12 months (%) 60.9 38.5-80.3 72.9 62.9-81.5 70.6 61.5-78.6
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corrected cure rates at day 28 and 42 for the PP analysis
were 100.0% (95% CI 96.7-100.0) and 100.0% (95% CI
96.5-100.0), respectively (Table 2). The uncorrected cure
rates at day 28 for the ITT analysis were 93.3% (95% CI
87.2-97.1) and 86.6% (95% CI 79.1-92.1), respectively
(Table 2). The corrected cure rates at day 28 for the
ITT analysis were 94.1% (95% CI 88.2-97.6) and 87.3%
(95% CI 79.9-92.7), respectively (Table 2). Using survival
analysis, the day 42 cure rate uncorrected and corrected
by genotyping was 99.1% and 100.0%, respectively.
E i g h tp a t i e n t s( 6 . 7 % )w e r ee x c l u d e df r o mt h eP Pa n a -
lysis, when they presented with parasitaemia with a dif-
ferent species, P. vivax (Table 2). 50% (4/8) of the
patients with P. vivax parasitaemia during follow-up
were symptomatic at the time. The median age was 5
years with a range of 3-18 years and did not differ sig-
nificantly for those that were symptomatic and those
that were not. The parasite density for those that were
symptomatic ranged from 120 to 80,640 parasite/μL,
whereas for those without symptoms the range was 360
to 31,440 parasite/μL. The median time to appearance
of parasitaemia with P. vivax was 35 days (interquartile
range 28-37.5 days). Gender, age group, and presence of
gametocytes on day 0 were explored as potential predic-
tors of recurrent parasitaemia with a different species,
but none were found to be significant.
Treatment with AL resulted in rapid clearance of
parasites and resolution of fever. All but 8 (6.9%)
patients had cleared their peripheral parasitaemia by
day 2 and only one remained positive till day 3 (0.9%)
(Table 3 and Figure 2). A review of parasite clearance
data from several studies n o t e dt h a tp o s i t i v eb l o o d
smears on day 3 was found to be a good predictor of
subsequent treatment failure and a simple screening
measure for artemisinin resistance [31]. Children aged
≤ 5 years were more likely to have persistent parasitae-
mia on day 2 compared to those >5 years (p < 0.01).
Of the 118 patients with fever (either by subjective
report or measured axillary temperature ≥37.5°C) on
day 0, 34.8% (n = 41) reported persistent fever on day
1 and only 7.0% (n = 8) by day 3. Restricting classifica-
tion of fever to only those with recorded axillary tem-
perature ≥37.5°C, 52.1% (62/119) were febrile on day 0
which decreased to only 8.5% (10/118) on day 1 and
none by day 2. All patients with gametocytes on day 0
had persistent gametocytaemia on day 2. No gameto-
cytes were noted after day 3 for those ≤5 years of age.
After day 21, no gametocyte carriers were found in
either age group. Excluding those with gametocytes on
day 0, no new carriers were identified during the 42-
day follow-up.
All day 0 slides submitted to the national laboratory at
EHNRI for quality control showed the same species
result except for two slides, which were diagnosed at the
national laboratory as negative. Both blood smears were
of very low level parasitaemia levels ranging from 1,240-
1,640 parasites/μL and the possibility of an oversight at
the national laboratory cannot be ruled out.
Laboratory outcomes
Mean haemoglobin for all patients increased, from 12.6
g/dL (standard deviation (SD) 2.5) on day 0 to 13.5 g/dL
(SD 1.8) on day 42. For children ≤5 years of age, it
increased from 10.4 g/dL (SD 1.8) to 12.0 g/dL (SD 1.1)
and for those >5 years of age from 13.2 g/dL (SD 2.3) to
1 3 . 8g / d L( S D1 . 8 )( T a b l e2 ) .T h em e a nd i f f e r e n c ei n
haemoglobin levels between day 42 and 0 was 1.9 (SD
Table 2 Treatment outcomes after day 28 and 42
Duration of follow-up
Outcome Day 28 Day 42
N = 119 N = 119
No treatment outcome 4 (3.4%) 7 (5.9%)
Lost to follow-up 1 4
Missed evening dose 3 3
Infection with different species 3 (2.5%) 8 (6.7%)
Failure
Early Treatment Failure 0 0
Late Clinical Failure 0 0
Late Parasitological Failure 1 1
Adequate Clinical and Parasitological Response -uncorrected 111 (93.3%) 103 (86.6%)
Cure rates-Per Protocol, PCR uncorrected (95% CI) 99.1% (95.1-100.0) 99.0% (94.8-100.0)
Cure rates-Per Protocol, PCR corrected (95% CI) 100% (96.7-100.0) 100% (96.5-100.0)
Cure rates-Intention-to-treat, PCR uncorrected (95% CI) 93.3% (87.2-97.1) 86.6% (79.1-92.1)
Cure rates- Intention-to-treat, PCR corrected (95% CI) 94.1% (88.2-97.6) 87.3% (79.9-92.7)
Abbreviations: CI- confidence interval
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>5 years (p < 0.01 for both comparisons).
Whole blood capillary lumefantrine level testing from
filter paper for the one treatment failure recovered 587.2
ng/mL of lumefantrine on day 7 with < 280 ng/ml pre-
viously identified to predict treatment failure.
Adverse events
AL treatment was well tolerated. There were no serious
adverse events. Four (3.5%) patients complained of
cough, which was the most common complaint, fol-
lowed by nausea and vomiting in three patients (2.6%).
Discussion
This study showed that AL remains an efficacious and
well-tolerated regimen in central Ethiopia. The high
cure rates noted in this study are consistent with the
baseline assessment conducted in 2003 prior to the
scale-up of ACT [13], more recent studies in Ethiopia
[14,15], and studies from elsewhere in Africa [17,32-36].
A recent meta-analysis of 32 published randomized stu-
dies of AL efficacy reported a 28-day PCR-corrected
parasitological cure rate of 97% [17]. Depending on the
methodology used, the cure rate for this study at day 28
ranged from 93-100% and at day 42 from 87-100%. Due
to the very small number of failures, it was not possible
to identify any predictors of treatment failures.
The rate of fever and parasite clearance was consistent
with previous studies [37,38]. The study noted only one
(0.9%) day 3 microscopically-positive P. falciparum case,
after AL therapy who was ultimately classified as ACPR.
The emerging resistance to artemisinins on the Thai-
Cambodian border has been characterized by slow para-
site clearance in vivo [19,20] and increased day 3 posi-
tive cases [19]. The review of parasite clearance times
noted that artemisinin resistance was highly unlikely
given the currently recommended 3-day ACT if the pro-
portion of day 3 positive smears is <3% [31]. To date in
Africa, no day 3 positives [37,38] to very few [39,40] [up
to 1 percent] have been reported, and no resistance to
AL has been reported [17]. However, with increasing
parasite clearance times and proportion of cases positive
on day 3 to artemisinin combination and monotherapies
on the Thai-Cambodia border, efficacy studies of ACT
should consider reporting parasite clearance times, or at
least day 3 positivity rates, more consistently.
Table 3 Secondary outcomes stratified by under 5 years of age and over 5 years of age
Outcome ≤5 years of age >5 years of age Total
Fever*, n/N (%)
Day 1 9/23 (39.1) 32/95 (33.7) 41/118 (34.8)
Day 2 1/22 (4.6) 10/94 (10.6) 11/116 (9.5)
Day 3 0/21 (0) 8/94 (8.5) 8/115 (7.0)
Parasitaemia, n/N (%)
Day 2 5/22 (22.7) 3/94 (3.2) 8/116 (6.9)
Day 3 1/21 (4.8) 0/94 (0) 1/115 (0.9)
Gametocytaemia, n/N (%)
Day 2 6/22 (27.3) 8/94 (8.5) 14/116 (12.1)
Day 3 1/21 (4.8) 5/94 (5.3) 6/115 (5.2)
Day 7 0 4/94 (4.3) 4/115 (3.5)
Day 14 0 1/94 (1.1) 1/115 (0.9)
Mean Haemoglobin g/dL, mean (SD)
Day 28 12.0 (1.2) 13.7 (1.8) 13.4 (1.8)
Day 42 12.0 (1.1) 13.8 (1.8) 13.5 (1.8)
Mean Difference in Haemoglobin Day 0 to 42 g/dL, (SD) 1.9 (1.9) 0.7 (2.1) 0.9 (2.1)
*Subjective fever or axillary temperature ≥37.5°C
Figure 2 Geometric Mean Parasite Density by day stratified by
≤5 years of age and >5 year of age with 95% confidence
limits.
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patients to our protocol, which was based on the stan-
dard WHO protocol, would have been easily accom-
plished and added another time point in defining the
rate of parasite clearance.
The AL side-effects noted in this study are consistent
with the ones previously reported [32,33,36,40,41]. A
review of the safety profile of AL reported that most
adverse events were mild or moderate in severity, com-
mon in both adults and children, and typical of symp-
toms of malaria [16]. Similar to this study, other studies
from Africa have reported cough as the most common
adverse event following AL therapy for P. falciparum
infection [15,37]. However, the frequency was much
lower in the current study, with only 3.5% patients
experiencing cough compared to 29-46% in the other
studies [15,37].
The study noted a significant improvement in haemo-
globin from day 0 to 42. However, children with Hg <
10 g/dL received concomitant therapy with iron, folate,
and mebendazole. A previous AL efficacy study from
Ethiopia noted no significant Hg change after 28 days in
the setting of no concomitant anaemia treatment and
cited high rates of helminthic infections in the study
area as a potential reason. Nonetheless, other efficacy
studies conducted without concomitant anaemia treat-
ment have noted significant improvement of haemoglo-
bin levels [39,42,43].
Marked variability in drug absorption has been noted
with lumefantrine administration [27] and the evaluation
of lumefantrine levels have not been included in the
standard WHO protocol although others have argued
for measurement of day 7 drug level as a routine com-
ponent of anti-malarial drug trials [44]. However, studies
have reported plasma lumefantrine concentration of 280
ng/ml seven days from the start of treatment as a useful
cut-off value for determining the risk of therapeutic fail-
ure [27,45]. Furthermore, capillary sampling was shown
to be a suitable alternative to venous sampling [46].
Although, 587 ng/ml of lumefantrine was recovered
from the one late parasitological failure on day 7 from
filter paper, the methodology to consistently and accu-
rately recover lumefantrine from filter paper samples is
problematic. Although, the treatment of filter paper
with tartaric acid prior to blood collection has been
shown to improve recovery of lumefantrine [30], the uti-
lity of testing lumefantrine levels from filter paper to aid
in accurately determining treatment failure remains
challenging.
Recurrent parasitaemia with P. vivax during follow-up
of P. falciparum efficacy studies have been reported
from throughout Asia from Thailand [19,47,48], Cambo-
dia [19], Papua [41], and Papua New Guinea [49], and
more recently from Ethiopia [14,15]. The reason for the
high rate of P. vivax parasitaemia found during follow-
up, in general, is not clear, but the following hypotheses
are possible: 1) initial co-infection where concurrent P.
falciparum acutely suppresses P. vivax parasitaemia to
levels below microscopic detection, 2) P. falciparum
infection and its treatment might somehow activate dor-
mant hypnozoites leading to P. vivax relapse, 3) new
infection with P. vivax during the follow-up duration
[50], or 4) activation of dormant hypnozoites is timed to
seasonal peak transmission season coincident to a
recently treated P. falciparum infection. Although the
mechanism is unknown, the rate of subsequent P. vivax
infection in the various studies noted lower rates when
P. falciparum was treated with an effective drug with a
longer half-life. For example, treatment of P. falciparum
with dihydroartemisinin-piperaquine (piperaquine mean
terminal elimination half-life is 28 days [51]) resulted in
lower recurrent P. vivax compared to AL (lumefantrine
mean terminal elimination half-life is 4.5 days [27])
[41,49]. The median time to recurrent parasitaemia with
P. vivax in the study was 35 days after 42 days of fol-
low-up, which presumably could have been longer had a
longer acting, effective ACT been tested. The high rates
of subsequent parasitaemia with P. vivax noted in this
P. falciparum in vivo study, highlights the special chal-
lenges that P. vivax will pose for malaria control and
elimination in Ethiopia and, indeed, the Horn of Africa.
Even with high efficacy of AL in Ethiopia, the effec-
tiveness of this drug will not be optimally realized if
patients are not accessing the drug in a timely manner
or if patients do not adhere to the treatment regimen.
The Malaria Indicator Survey from 2007 in Ethiopia
noted that only 3.9% of children with fever were treated
with an anti-malarial within 24 hours and of those trea-
t e d ,m o r er e c e i v e dC Qt h a nA L[ 5 2 ] .I na ne f f o r tt o
improve supply of and access to free, prompt malaria
diagnosis and treatment [21], Ethiopia has trained and
deployed over 30,000 health extension workers to man-
age malaria at the community-level health posts. The
impact of this large-scale deployment of AL was demon-
strated in Tigray Regional State, where a two year study
of community-based deployment of AL significantly
lowered risk of malaria-specific mortality by 37% [2].
Conclusions
Even after several years of free universal access to ACT,
AL remains a highly efficacious treatment for uncompli-
cated P. falciparum infection in Ethiopia. The routine
monitoring of first-line regimens is crucial for effective
malaria control and national policy decision-making. In
addition, some simple alterations of the current WHO
protocol and reporting conventions could enhance a
globally coordinated vigilance for early signals of declin-
ing efficacy of artemisinins.
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